Pharmaceutical cannabis sales surge, clinical trials seeing broader disease focusProactive Investors • 08/30/23
Wall Street Analysts See a 51.66% Upside in Jazz (JAZZ): Can the Stock Really Move This High?Zacks Investment Research • 08/10/23
Jazz (JAZZ) Q2 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 08/10/23
Jazz Pharmaceuticals (JAZZ) Q2 Earnings and Revenues Top EstimatesZacks Investment Research • 08/09/23
Jazz Pharmaceuticals Announces Second Quarter 2023 Financial Results and Raises 2023 Full Year Financial GuidancePRNewsWire • 08/09/23
Is a Surprise Coming for Jazz Pharmaceuticals (JAZZ) This Earnings Season?Zacks Investment Research • 08/08/23
Jazz Pharmaceuticals to Report 2023 Second Quarter Financial Results on August 9, 2023PRNewsWire • 07/26/23
Jazz Pharmaceuticals (JAZZ) to Report Q2 Results: Wall Street Expects Earnings GrowthZacks Investment Research • 07/26/23
Jazz Pharmaceuticals Receives CHMP Positive Opinion for JZP458 (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic LymphomaPRNewsWire • 07/21/23
Wall Street Analysts Think Jazz (JAZZ) Could Surge 54.74%: Read This Before Placing a BetZacks Investment Research • 07/19/23
Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract CancersPRNewsWire • 06/02/23
Jazz Pharmaceuticals Demonstrates Continued Leadership in Sleep Medicine with New Data Presentations at SLEEP 2023PRNewsWire • 05/31/23
Jazz Pharmaceuticals to Participate in the 2023 Goldman Sachs Global Healthcare ConferencePRNewsWire • 05/30/23